Intravenous Immunoglobulin (IVIg) Market is Growing at a Trendy Speed at a Healthy CAGR of 5.9% During Forecast 2018-2023
Intravenous Immunoglobulin (IVIg), a
compound comprising of immune proteins (globulins) is administered into the
bloodstream to treat patients with the inefficient or damaged immune systems. IVIg
suffices the required antibodies by the human body to fight out the immune
deficiency, and the consequent infectious attacks. Immunodeficiency Disorder
could be a hereditary issue (Primary disorders), or caused due to the exposure
to infections, mainly through bodily fluids, along with the cancer drugs and
chemotherapy, aging is one of the key risk factor too that could put someone at
greater risk of a damaged immune system.
Market Research
Future (MRFR) has recently published a study report giving out the complete
market forecast up to 2023. In its analysis, MRFR asserts that the global Intravenous
Immunoglobulin Market growing further will reach USD 8337.2
Million by 2023, registering 5.9% CAGR during
2017 to 2023.
Leveraging to the modern age, people
have adopted the heady & unhealthy lifestyles which mirror the prevalence
of damaged immune system. Factors such as immense of stress, lack of good
quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling
the prevalence of Immunodeficiency Disorder. And, the augmented prevalence is
predominantly driving the market growth.
Acknowledging the
kind of the growth the market perceives currently;
The augmenting
demand for alternate immunoglobulin replacement therapies, increasing R&D
funding, rapidly developing healthcare infrastructure and increasing healthcare
expenditures are major driving forces for the market growth. Technological advancements transpired in the
medical science, are fostering the market growth exponentially, bringing up novel
treatment procedures, & medications in the field of IVIg.
Major Players:
·
Abeona
Therapeutics
·
BDI Pharma
·
China
Biologic Products
·
Biotest AG
·
Grifols Inc
·
CSL Behring
Intravenous
Immunoglobulin Market – Competitive Analysis
The global IVIg market is fiercely competitive with the
presence of several large and small players operating in the market. These
market players acquire promising companies to expand in the fast-growing
markets, focusing on improving their market performance. The market structure
is dynamic due to the acquisition of local manufactures by the multinational
companies. Strategies like product innovations and technologies are creating
strong investment opportunities for the market players.
Intravenous
Immunoglobulin Market – Segments
·
Global Intravenous Immunoglobulin (IVIg) Market has
been segmented on the basis of type which comprise IgA (sub segments- IgA1 and
IgA2), IgD, IgE, IgG,.
·
On the basis of application it segmented into CIDP
(Progressive, Recurrent, Monophasic), Hypogammaglobulinemia (sub segments-
AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), Multifocal Motor Neuropathy,
Immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA),
common variable immunodeficiency (CVID), severe combined immunodeficiency),
Primary Humoral Immunodeficiency (Subsegments- B cell (antibody) deficiencies,
T cell deficiencies, Combination B and T cell deficiencies, Defective
phagocytes, Complement deficiencies, Unknown (idiopathic)), Myasthenia Gravis
(Sub segments- generalized myasthenia gravis, ocular myasthenia gravis,
Congenital myasthenia gravis, Transient neonatal myasthenia gravis),
Guillain-Barre syndrome (Sub segments- Acute inflammatory demyelinating
polyradiculoneuropathy (AIDP), Miller Fisher syndrome (MFS), Acute motor axonal
neuropathy (AMAN)and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki
disease, ITP (Sub segments- acute and chronic), and others.
Intravenous
Immunoglobulin Market – Geographical Analysis
On the other hand, Europe, the world’s
second-largest market for IVIg, is fostered by the high per capita income and
robust healthcare penetration in the region. The strong market growth in the
countries like Germany & France drives the regional market growth, large
scale. Attributing to the increasing investment in healthcare and rising number
of patients with immune system diseases, the market is projected to register a
phenomenal CAGR during the forecast period.
Asia Pacific market for the Intravenous
Immunoglobulin is expected to perceive an exponential growth. Owing to the huge
population and the burgeoning medical treatment market, India & China drive
the regional market growth. Vietnam, Thailand, and Malaysia among the other
South East Asian countries are projected to contribute significantly to the
regional market growth. With the growing Medical Tourism markets in India &
Malaysia the APAC region will register a significant CAGR during the review
period.
Comments
Post a Comment